The company announced an oversubscribed recent funding boost toward the preclinical development of its HHLA2 and IL18BP programs CANTON, Mass.–(BUSINESS WIRE)–April 3, 2024– Conformation-X ...
Naturally occurring proteins often change their shape, or conformation, as their environment changes. This property is key to the way they do their jobs in biology. But designing similar switches in ...
CANTON, Mass.--(BUSINESS WIRE)--Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results